-
公开(公告)号：US20210171648A1
公开(公告)日：2021-06-10
申请号：US17077456
申请日：2020-10-22
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. UNDERWOOD , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US20200317797A1
公开(公告)日：2020-10-08
申请号：US16906587
申请日：2020-06-19
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. UNDERWOOD , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US20200317796A1
公开(公告)日：2020-10-08
申请号：US16808074
申请日：2020-03-03
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Marc VAN DIJK , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Hao TANG , David A. SAVITSKY , Jeremy WAIGHT , Nicholas S. WILSON
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , G01N33/68
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20200079861A1
公开(公告)日：2020-03-12
申请号：US15781043
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. Underwood , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US20190010239A1
公开(公告)日：2019-01-10
申请号：US15962673
申请日：2018-04-25
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Ana M. GONZALEZ , Nicholas S. WILSON , Dennis J. UNDERWOOD , Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Roberta ZAPPASODI , Taha MERGHOUB , Jedd David WOLCHOK , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
公开(公告)号：US20180355051A1
公开(公告)日：2018-12-13
申请号：US15962752
申请日：2018-04-25
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Ana M. GONZALEZ , Nicholas S. WILSON , Dennis J. UNDERWOOD , Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Roberta ZAPPASODI , Taha MERGHOUB , Jedd David WOLCHOK , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
公开(公告)号：US20220380479A1
公开(公告)日：2022-12-01
申请号：US17662606
申请日：2022-05-09
申请人： AGENUS INC. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Dennis J. UNDERWOOD , Ekaterina V. BREOUS-NYSTROM , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Marc VAN DIJK
IPC分类号： C07K16/28
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.
-
公开(公告)号：US20190352410A1
公开(公告)日：2019-11-21
申请号：US16384116
申请日：2019-04-15
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Marc VAN DIJK , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Hao TANG , David A. SAVITSKY , Jeremy WAIGHT , Nicholas S. WILSON
IPC分类号： C07K16/28 , G01N33/68 , A61K45/06 , A61K39/395
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20210324097A1
公开(公告)日：2021-10-21
申请号：US17192842
申请日：2021-03-04
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K39/395 , G01N33/68
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or diminish, deactivate, or suppress OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., diminishes, deactivates, or suppresses OX40 activity.
-
公开(公告)号：US20200339698A1
公开(公告)日：2020-10-29
申请号：US16744163
申请日：2020-01-15
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Ana M. GONZALEZ , Nicholas S. WILSON , Dennis J. UNDERWOOD , Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Roberta ZAPPASODI , Taha MERGHOUB , Jedd David WOLCHOK , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.03 秒)
